Geron Stops IMpactMF After Survival Futility Review
On 28 October Geron discontinued the 327-patient Phase III IMpactMF trial after its independent monitoring committee judged an overall-survival benefit unlikely in JAK-inhibitor relapsed or refractory myelofibrosis. This is a negative program signal, while…
